Observer-blind Study to Evaluate Efficacy, Safety, and Immunogenicity of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A
Phase of Trial: Phase III
Latest Information Update: 01 Jun 2017
At a glance
- Drugs GSK 1437173A (Primary)
- Indications Herpes zoster
- Focus Registrational; Therapeutic Use
- Acronyms ZOSTER-002
- Sponsors GlaxoSmithKline
- 29 Mar 2017 Status changed from active, no longer recruiting to completed.
- 25 Feb 2016 Planned number of patients changed from 1847 to 1846, according to ClinicalTrials.gov record.
- 19 Feb 2016 Planned primary completion date changed from 1 Jan 2017 to 1 Nov 2016 as reported by ClinicalTrials.gov record.